These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3966545)

  • 1. Regulation of plasma lipid levels by plasma viscosity in nephrotic rats.
    Yedgar S; Eilam O; Shafrir E
    Am J Physiol; 1985 Jan; 248(1 Pt 1):E10-4. PubMed ID: 3966545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High density lipoproteinuria in nephrotic syndrome.
    de Mendoza SG; Kashyap ML; Chen CY; Lutmer RF
    Metabolism; 1976 Oct; 25(10):1143-9. PubMed ID: 184367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats.
    Hirano T; Mamo JC; Nagano S; Sugisaki T
    Nephron; 1991; 58(1):95-100. PubMed ID: 1857487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.
    Gherardi E; Calandra S
    Biochim Biophys Acta; 1982 Feb; 710(2):188-96. PubMed ID: 7066357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of non-HDL fraction to oxidation in experimental nephrotic syndrome.
    Dirican M; Taş S; Sarandöl E; Tokullugil HA
    Kobe J Med Sci; 1998 Dec; 44(5-6):235-45. PubMed ID: 10401226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperlipoproteinemia of aminonucleoside-induced nephrotic syndrome--modulation by glucocorticoids and triiodothyronine.
    Shafrir E
    Isr J Med Sci; 1996 Jun; 32(6):390-7. PubMed ID: 8682644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viscosity regulates apolipoprotein A-1 gene expression in experimental models of secondary hyperlipidemia and in cultured hepatocytes.
    Nuño P; Hernández A; Mendoza-Figueroa T; Panduro A
    Biochim Biophys Acta; 1997 Feb; 1344(3):262-9. PubMed ID: 9059516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and urine lipoproteins during the development of nephrotic syndrome induced in the rat by adriamycin.
    Calandra S; Tarugi P; Ghisellini M; Gherardi E
    Exp Mol Pathol; 1983 Dec; 39(3):282-99. PubMed ID: 6416889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the turnover of triglyceride and esterified cholesterol in subjects with the nephrotic syndrome.
    McKenzie IF; Nestel PJ
    J Clin Invest; 1968 Jul; 47(7):1685-95. PubMed ID: 5658595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low density lipoprotein metabolism in rats with puromycin aminonucleoside-induced nephrotic syndrome.
    Joven J; Masana L; Villabona C; Vilella E; Bargalló T; Trias M; Figueras M; Turner PR
    Metabolism; 1989 May; 38(5):491-5. PubMed ID: 2725289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the interrelationship between hepatic carnitine, fatty acid oxidation, and triglyceride biosynthesis in nephrosis.
    al-Shurbaji A; Berglund L; Berge RK; Cederblad G; Humble E
    Lipids; 1997 Aug; 32(8):847-52. PubMed ID: 9270976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glomerular sclerosis in nephrotic rats. Comparison of the long-term effects of adriamycin and aminonucleoside.
    Grond J; Weening JJ; Elema JD
    Lab Invest; 1984 Sep; 51(3):277-85. PubMed ID: 6471809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on abnormal lipid metabolism in experimental nephrotic syndrome.
    Agbedana ED; Yamamoto T; Moriwaki Y; Suda M; Takahashi S; Higashino K
    Nephron; 1993; 64(2):256-61. PubMed ID: 8321360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 3-thiadicarboxylic acid on lipid metabolism in experimental nephrosis.
    al-Shurbaji A; Skorve J; Berge RK; Rudling M; Björkhem I; Berglund L
    Arterioscler Thromb; 1993 Nov; 13(11):1580-6. PubMed ID: 8218098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis.
    Hirano T; Morohoshi T
    Nephron; 1992; 60(4):443-7. PubMed ID: 1584321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity of lovastatin in rats with experimentally induced nephrotic syndrome.
    Joven J; Vilella E; Camps J; Masana L; Turner PR; Simó JM; Villabona C
    Nephron; 1990; 56(4):399-404. PubMed ID: 2079999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity.
    Appel GB; Blum CB; Chien S; Kunis CL; Appel AS
    N Engl J Med; 1985 Jun; 312(24):1544-8. PubMed ID: 3858668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrotic hyperlipidemia: primary abnormalities in both lipoprotein catabolism and synthesis.
    Kaysen GA
    Miner Electrolyte Metab; 1992; 18(2-5):212-6. PubMed ID: 1465061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome.
    Vaziri ND; Liang KH
    Circulation; 2004 Jul; 110(4):419-25. PubMed ID: 15262831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catabolism of very low density lipoproteins in experimental nephrosis.
    Garber DW; Gottlieb BA; Marsh JB; Sparks CE
    J Clin Invest; 1984 Oct; 74(4):1375-83. PubMed ID: 6480830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.